L'omacetaxine, nouveau traitement pour la mutation T315I

[cousineg]

ChemGenexs Marketing Authorization Application for Omacetaxine Mepesuccinate
Validated by the European Medicines Agency – 27 novembre 2009
http://ca.news.finance.yahoo.com/s/2711 ... inate.html

EMEA determines MAA for omacetaxine mepesuccinate for treatment of CML patients – 28 novembre 2009
http://www.news-medical.net/news/200911 ... ients.aspx

Omacetaxine may be viable treatment option for patients with T315I-positive CML – 5 décembre 2009
http://www.hemonctoday.com/article.aspx?rid=51171

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate
in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant
to Two or More Tyrosine Kinase Inhibitors –
Results of A Multicenter Phase 2/3 Study – 8 décembre 2009 – ASH2009
http://ash.confex.com/ash/2009/webprogr ... 22420.html

Omacetaxine shows promise against hard-to-treat CML – 8 décembre 2009
http://www.oncolink.org/resources/artic ... 2&id=16591

Chronic Myeloproliferative Neoplasias
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-i
nduced chronic myeloid leukemia and acute lymphoblastic leukemia in mice- 26 mars 2009
http://www.nature.com/leu/journal/v23/n ... 0952a.html

Omacetaxine study suggets it can eradicate leukemic stem cells may offer a breakthrough for CML - 26 mars 2009
http://www.breakthroughdigest.com/leuke ... h-for-cml/

[cousineg]

Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML - mars 2009
Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are the subject of an advance online publication in the journal Leukemia, ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today. The findings of this study provide new insights into the problem of minimal residual disease and may open the door to the development of a curative treatment strategy for some patients with CML.
http://www.physorg.com/news157272570.html

ChemGenex’s Omacetaxine Kills Leukemic Stem Cells in Human CML Models - juin 2009
New In Vitro Research with Omacetaxine in Human Cancer Stem Cells May Point to a Future Approach to Treating CML
http://www.businesswire.com/portal/site ... ewsLang=en

ChemGenex's Omacetaxine Kills Leukemic Stem Cells in Human CML Models - juin 2009
New In Vitro Research with Omacetaxine in Human Cancer Stem Cells May Point to a Future Approach to Treating CML
http://www.drugs.com/clinical_trials/ch ... -7468.html

[cousineg]

Avantages modestes avec l’omacétaxine : résultats de deux études cliniques - 18 février 2010
http://www.cmlsource.ca/modest.php?lang=2

[cousineg]

U.S. Food and Drug Administration’s Oncologic Drug Advisory Committee Recommends ChemGenex Validate a Diagnostic Prior to Approval of OMAPRO™ in Chronic Myeloid Leukemia Patients with T315I Mutation , 22 March 2010
http://www.earthtimes.org/articles/show ... 5975.shtml

FDA's Oncologic Drug Advisory Committee Recommends ChemGenex Pharmaceuticals Limited (CXS.AX) Validate a Diagnostic Prior to Approval of OMAPRO in Chronic Myeloid Leukemia Patients with T315I Mutation
3/23/2010
http://www.biospace.com/news_story.aspx ... 667&full=1

[cousineg]

Petition to the FDA Oncology Drug Advisory Committee (ODAC) on the Status of the drug Omacetaxine
....While we commend the work of the FDA and reviewing Omacetaxine, and indeed all of our drugs currently used to treat this disease, we are dismayed by the sudden change of policy. We are asking the FDA to re-visit their recommendation and allow Omacetaxine to come to market while the company (ChemGenex) works with labs to standardize mutation testing....
Voir extrait de http://www.newcmldrug.com/Discuss/reply ... eply=27321

[cousineg]

Successful treatment using omacetaxine for a patient with CML and BCR-ABL2 35INS
Kris M. Mahadeo and Peter D. Cole
Blood, 6 May 2010, Vol. 115, No. 18, pp. 3852.
http://bloodjournal.hematologylibrary.o ... 15/18/3852

[cousineg]

.........
Voir aussi Mutation T315I
.........

[cousineg]

.............
Voir aussi Omacetaxine
.............

[cousineg]

..........
La FDA a approuvé l'omacetaxine.

FDA Approves Omacetaxine (Synribo) for CML
October 26, 2012, Cancer Network

FDA approves Synribo for chronic myelogenous leukemia
October 26, 2012, FDA
..........